CardioCel® is the first in a potential portfolio of tissue products being developed by Admedus using its proprietary ADAPT® tissue engineering process.

CardioCel®  is a single-ply, bio-scaffold material that remains functional, durable and free from calcification. The bio-scaffold  is used to repair congenital heart deformities and more complex heart defects, it is also used to reconstruct dysfunctional heart valves and valve leaflets.

Admedus hopes that in the future, CardioCel® may also be used for the manufacture of replacement tissue heart valves.

Benefits of use

CardioCel - TheatreCardioCel® is not only durable, but its natural flexibility and elasticity makes it easier to handle and use. Due to its tensile strength it is suitable for use in pressured environments like valves. CardioCel® also actively facilitates host tissue regeneration post-implantation.

Long-term clinical studies using CardioCel® have shown no (or minimal) calcification seven years post-implantation, with strong ingrowth of normal heart tissue around the scaffold and blood-flow through and around the implant.

CardioCel® is available at leading heart centres around the world and has the potential for use across a wide range of clinical applications.

How it works

CardioCel® is approved/cleared for sale in Europe, the US, Canada, Hong Kong, Malaysia, Singapore, New Zealand and Middle East and North Africa Region. CardioCel® is also available under the special access scheme in Australia and other select countries.

CardioCel® is currently used by leading heart centres around the world and has been implanted in thousands of patients to date.

CardioCel® is an implantable medical device and is only available on the recommendation of a suitable qualitfied healthcare professional in those countries where it has been approved or cleared for sale. This site is for the use of healthcare professionals only.

For more information on how CardioCel works, please contact us here.